Table 2.
Best response to subsequent therapy*
| Available information on first subsequent therapy | Fulvestrant 500mg (n = 362) | Fulvestrant 250mg (n = 374) |
|---|---|---|
| 230 | 239 | |
| Category of subsequent therapy, No. | ||
| Radiotherapy | 8 | 8 |
| Endocrine therapy | 80 | 74 |
| Chemotherapy | 135 | 142 |
| HER2 directed | 0 | 1 |
| Unknown/other | 3 | 5 |
| Fulvestrant† | 4 | 9 |
| Best response to subsequent therapy, No. (%) | ||
| Complete response | 2 (0.9) | 0 |
| Partial response | 17 (7.4) | 20 (8.4) |
| Stable disease | 57 (24.8) | 77 (32.2) |
| Progressive disease | 77 (33.5) | 68 (28.5) |
| Not evaluable | 77 (33.5) | 74 (31.0) |
* Subsequent endocrine therapy included: anastrozole, exemestane, letrozole, medroxy progesterone, megestrol acetate, and tamoxifen. HER2 = human epidermal growth factor receptor 2.
† Fulvestrant was either given at a dose of 250mg or the dose was not specified.